116 related articles for article (PubMed ID: 37738462)
21. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
22. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
23. Partial break in tolerance of NKG2A
Rathmann S; Keck C; Kreutz C; Weit N; Müller M; Timmer J; Glatzel S; Follo M; Malkovsky M; Werner M; Handgretinger R; Finke J; Fisch P
Bone Marrow Transplant; 2017 Aug; 52(8):1144-1155. PubMed ID: 28481352
[TBL] [Abstract][Full Text] [Related]
24. [Expression of NKG2D and NKG2A with their ligands MHC-I A/B and HLA-E in acute leukemia patients and its significance].
Ge SJ; Duan LN; Luo Y; Suo TL; Lu CR; Tang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):312-6. PubMed ID: 21518478
[TBL] [Abstract][Full Text] [Related]
25. Association of NKG2A with treatment for chronic hepatitis C virus infection.
Harrison RJ; Ettorre A; Little AM; Khakoo SI
Clin Exp Immunol; 2010 Aug; 161(2):306-14. PubMed ID: 20550548
[TBL] [Abstract][Full Text] [Related]
26. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
27. NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.
Hò GT; Celik AA; Huyton T; Hiemisch W; Blasczyk R; Simper GS; Bade-Doeding C
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575403
[TBL] [Abstract][Full Text] [Related]
28. Human liver-derived CXCR6
Lunemann S; Langeneckert AE; Martrus G; Hess LU; Salzberger W; Ziegler AE; Löbl SM; Poch T; Ravichandran G; Sauter J; Schmidt AH; Schramm C; Oldhafer KJ; Altfeld M; Körner C
J Leukoc Biol; 2019 Jun; 105(6):1331-1340. PubMed ID: 30779432
[TBL] [Abstract][Full Text] [Related]
29. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
Kamiya T; Seow SV; Wong D; Robinson M; Campana D
J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
[TBL] [Abstract][Full Text] [Related]
30. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia.
Hallner A; Bernson E; Hussein BA; Ewald Sander F; Brune M; Aurelius J; Martner A; Hellstrand K; Thorén FB
Blood; 2019 Mar; 133(13):1479-1488. PubMed ID: 30647027
[TBL] [Abstract][Full Text] [Related]
31. The effect of mifepristone on the peripheral blood natural killer cell's cytotoxicity and expression of CD94/NKG2A and NKG2D during the implantation phase.
Chen XY; Zhuang YL; Li L; Zhang WW; Huang LL
Fertil Steril; 2010 May; 93(8):2615-20. PubMed ID: 19880106
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
[TBL] [Abstract][Full Text] [Related]
33. Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.
Rathmann S; Glatzel S; Schönberg K; Uhrberg M; Follo M; Schulz-Huotari C; Kaymer M; Veelken H; Finke J; Fisch P
Biol Blood Marrow Transplant; 2010 Apr; 16(4):469-81. PubMed ID: 20044012
[TBL] [Abstract][Full Text] [Related]
34. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis.
Galandrini R; Porpora MG; Stoppacciaro A; Micucci F; Capuano C; Tassi I; Di Felice A; Benedetti-Panici P; Santoni A
Fertil Steril; 2008 May; 89(5 Suppl):1490-6. PubMed ID: 17706207
[TBL] [Abstract][Full Text] [Related]
35. Characterization of KIR + NKG2A + Eomes- NK-like CD8+ T cells and their decline with age in healthy individuals.
Kasakovski D; Zeng X; Lai J; Yu Z; Yao D; Chen S; Zha X; Li Y; Xu L
Cytometry B Clin Cytom; 2021 Jul; 100(4):467-475. PubMed ID: 32830898
[TBL] [Abstract][Full Text] [Related]
36. Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.
Lopez-Vergès S; Milush JM; Schwartz BS; Pando MJ; Jarjoura J; York VA; Houchins JP; Miller S; Kang SM; Norris PJ; Nixon DF; Lanier LL
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14725-32. PubMed ID: 21825173
[TBL] [Abstract][Full Text] [Related]
37. Expression of NKG2A inhibitory receptor on cytotoxic lymphocytes as an indicator of severity in Corona Virus Disease 2019 (COVID-19) patients.
Yasin MM; Shehata IH; Elsheikh NG; Elsayed MS
Egypt J Immunol; 2021 Jul; 28(3):157-167. PubMed ID: 34453787
[TBL] [Abstract][Full Text] [Related]
38. Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self.
Michen S; Frosch J; Füssel M; Schackert G; Momburg F; Temme A
Cytotherapy; 2020 Jul; 22(7):354-368. PubMed ID: 32451262
[TBL] [Abstract][Full Text] [Related]
39. CD8
Chen Y; Xin Z; Huang L; Zhao L; Wang S; Cheng J; Wu P; Chai Y
Front Immunol; 2019; 10():3002. PubMed ID: 32010126
[No Abstract] [Full Text] [Related]
40. The repertoire of killer cell Ig-like receptor and CD94:NKG2A receptors in T cells: clones sharing identical alpha beta TCR rearrangement express highly diverse killer cell Ig-like receptor patterns.
Uhrberg M; Valiante NM; Young NT; Lanier LL; Phillips JH; Parham P
J Immunol; 2001 Mar; 166(6):3923-32. PubMed ID: 11238637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
